Identification of genes showing differential expression in antisense K- ras-transduced pancreatic cancer cells with suppressed tumorigenicity

Cancer Research

Volumn 59, Issue 21, 1999, Pages 5565-5571

  Ohnami, Shumpei ^a   Matsumoto, Nobuyuki ^a   Nakano, Masaru ^a   Aoki, Kazunori ^a   Nagasaki, Koichi ^a   Sugimura, Takashi ^a   Terada, Masaaki ^a   Yoshida, Teruhiko ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOFERRITIN; COMPLEMENTARY DNA; KALININ; MATRILYSIN; MEMBRANE PROTEIN; MESSENGER RNA; PROTEASOME; RIBOSOME PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEIC ACID PROBE; ONCOGENE K RAS; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL;

BLOTTING, NORTHERN; DNA, COMPLEMENTARY; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MATRIX METALLOPROTEINASE 7; MITOCHONDRIA; MODELS, GENETIC; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENE PROTEINS; PANCREAS; PANCREATIC NEOPLASMS; PEPTIDE ELONGATION FACTOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0033229913     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Sugimura, T. Multistep carcinogenesis: a 1992 perspective. Science (Washington DC), 258: 603-607, 1992.
2. Howe, J. R., and Conlon, K. C. The molecular genetics of pancreatic cancer. Surg. Oncol., 6: 1-18, 1997.
3. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53: 549-554, 1988.
4. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
5. Mariyama, M., Kishi, K., Nakamura, K., Obata, H., and Nishimura, S. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn. J. Cancer Res., 80: 622-626, 1989.
6. Motojima, K., Urano, T., Nagata, Y., Shiku, H., Tsunoda, T., and Kanematsu, T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am. J. Gastroenterol., 86: 1784-1788, 1991.
7. Lee, K. H., Lee, J. S., Suh, C., Kim, S. W., Kim, S. B., Lee, J. H., Lee, M. S., Park, M. Y., Sun, H. S., and Kim, S. H. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer (Phila.), 75: 2794-2801, 1995.
8. Ruggeri, B. A., Huang, L., Berger, D., Chang, H., Klein-Szanto, A. J., Goodrow, T., Wood, M., Obara, T., Heath, C. W., and Lynch, H. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer (Phila.), 79: 700-716, 1997.
9. Simon, B., Weinel, R., Hohne, M., Watz, J., Schmidt, J., Kortner, G., and Arnold, R. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology, 106: 1645-1651, 1994.
10. Kaino, M. Alterations in the tumor suppressor genes p53, RB, p16/MTS1, and p15/MTS2 in human pancreatic cancer and hepatoma cell lines. J. Gastroenterol., 32: 40-46, 1997.
11. Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Washington DC), 277: 350-353, 1996.
12. Yamada, H., Sakamoto, H., Taira, M., Nishimura, S., Shimosato, Y., Terada, M., and Sugimura, T. Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes. Jpn. J. Cancer Res., 77: 370-375, 1986.
13. Horii, A., Nakatsuru, S., Miyoshi, Y., Ichii, S., Nagase, H., Ando, H., Yanagisawa, A., Tsuchiya, E., Kato, Y., and Nakamura, Y. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res., 52: 6696-6698, 1992.
14. Huang, L., Lang, D., Geradts, J., Obara, T., Klein-Szanto, A. J., Lynch, H. T., and Ruggeri, B. A. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol. Carcinog., 15: 85-95, 1996.
15. Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., and Kern, S. E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res., 56: 5360-5364, 1996.
16. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., and Testa, J. R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog., 21: 81-86, 1998.
17. Korc, M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am., 7: 25-41, 1998.
18. Ebert, M., Yokoyama, M., Friess, H., Buchler, M. W., and Korc, M. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res., 54: 5775-5778, 1994.
19. Aoki, K., Yoshida, T., Sugimura, T., and Terada, M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res., 55: 3810-3816, 1995.
20. Aoki, K., Yoshida, T., Matsumolo, N., Ide, H., Sugimura, T., and Terada, M. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol. Carcinog., 20: 251-258, 1997.
21. Yanagisawa, A., Ohtake, K., Ohashi, K., Hori, M., Kitagawa, T., Sugano, H., and Kato, Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res., 53: 953-956, 1993.
22. Ochiai, A., Yasui, W., and Tahara, E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn. J. Cancer Res., 76: 1064-1071, 1985.
23. Sekiguchi, M., Sakakibara, K., and Fujii, G. Establishment of cultured cell lines derived from a human gastric carcinoma. Jpn. J. Exp. Med., 48: 61-68, 1978.
24. Sakakibara, K., Suzuki, T., Motoyama, T., Watanabe, H., and Nagai, Y. Biosynthesis of an interstitial type of collagen by cloned human gastric carcinoma cells. Cancer Res., 42: 2019-2027, 1982.
25. Liang, P., and Pardee, A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (Washington DC), 257: 967-971, 1992.
26. Liang, P., Zhu, W., Zhang, X., Guo, Z., O'Connell, R. P., Averboukh, L., Wang, F., and Pardee, A. B. Differential display using one-base anchored oligo-dT primers. Nucleic Acids Res., 22: 5763-5764, 1994.
27. Akiyama, N., Sasaki, H., Ishizuka, T., Kishi, T., Sakamoto, H., Onda, M., Hirai, H., Yazaki, Y., Sugimura, T., and Terada, M. Isolation of a candidate gene, CAB1, for cholesterol transport to mitochondria from the c-ERBB-2 amplicon by a modified cDNA selection method. Cancer Res., 57: 3548-3553, 1997.
28. Sun, Y., Lin, J., Katz, A. E., and Fisher, P. B. Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res., 57: 18-23, 1997.
29. Ishikawa, T., Ichikawa, Y., Mitsuhashi, M., Momiyama, N., Chishima, T., Tanaka, K., Yamaoka, H., Miyazakic, K., Nagashima, Y., Akitaya, T., and Shimada, H. Matrilysin is associated with progression of colorectal tumor. Cancer Lett., 107: 5-10, 1996.
30. Ide, H., Katoh, M., Sasaki, H., Yoshida, T., Aoki, K., Nawa, Y., Osada, Y., Sugimura, T., and Terada, M. Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs. Oncogene, 14: 1377-1382, 1997.
31. Shen, R., Su, Z. Z., Olsson, C. A., and Fisher, P. B. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc. Natl. Acad. Sci. USA, 92: 6778-6782, 1995.
32. Pedersen, P. L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res., 22: 190-274, 1978.
33. Heerdt, B. G., Halsey, H. K., Lipkin, M., and Augenlicht, L. H. Expression of mitochondrial cytochrome c oxidase in human colonic cell differentiation, transformation, and risk for colonie cancer. Cancer Res., 50: 1596-1600, 1990.
34. Satake, K., Shim, K., Sowa, M., and Umeyama, K. Electron microscopic studies of human pancreatic adenocarcinoma. Eur. J. Surg. Oncol., 11, 125-135, 1985.
35. Takahashi, M., Arai, H., Kokubo, T., Furukawa, F., Kurata, Y., and Ito, N. An ultrastructural study of precancerous and cancerous lesions of the pancreas in Syrian golden hamsters induced by N-nitrosobis(2-oxopropyl)amine. Gann, 71: 825-831, 1980.
36. Golshani-Hebroni, S. G., and Bessman, S. P. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J. Bioenerg. Biomembr., 29: 331-338, 1997.
37. Cavalli, L. R., Varella-Garcia, M., and Liang, B. C. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ., 8: 1189-1198, 1997.
38. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (Lond.), 397: 441-446, 1999.
39. Su, Z., Goldstein, N. I., and Fisher, P. B. Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc. Natl. Acad. Sci. USA, 95: 1764-1769, 1998.
40. Bramhall, S. R., Neoptolemos, J. P., Stamp, G. W., and Lemoine, N. R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J. Pathol., 182: 347-355, 1997.
41. Tani, T., Lumme, A., Linnala, A., Kivilaakso, E., Kiviluoto, T., Burgeson, R. E., Kangas, L., Leivo, I., and Virtanen, I. Pancreatic carcinomas deposit laminin-5, preferably adhere to laminin-5, and migrate on the newly deposited basement membrane. Am. J. Pathol., 151: 1289-1302, 1997.
42. Sawada, R., Lowe, J. B., and Fukuda, M. E-selectin-dependent adhesion efficiency of colonie carcinoma cells is increased by genetic manipulation of their cell surface lysosomal membrane glycoprotein-1 expression levels. J. Biol. Chem., 268: 12675-12681, 1993.
43. Skrincosky, D. M., Allen, H. J., and Bernacki, R. J. Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptin-binding glycoproteins. Cancer Res., 53: 2667-2675, 1993.
44. Saitoh, O., Wang, W. C., Lotan, R., and Fukuda, M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J. Biol. Chem., 267: 5700-5711, 1992.
45. Cermak, J., Balla, J., Jacob, H. S., Balla, G., Enright, H., Nath, K., and Vercellotti, G. M. Tumor cell heme uptake induces ferritin synthesis resulting in altered oxidant sensitivity: possible role in chemotherapy efficacy. Cancer Res., 53: 5308-5313, 1993.
46. Lott, J. B., and Mackie, G. A. Isolation and characterization of cloned cDNAs that code for human ribosomal protein S6. Gene (Amst.), 65: 31-39, 1988.
47. Huang, J., Kwong, J., Sun, E. C., and Liang, T. J. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J. Virol., 70: 5582-5591, 1996.
48. Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S., and Ichihara, A. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA, 87: 7071-7075, 1990.